In:
Future Oncology, Future Medicine Ltd, Vol. 19, No. 3 ( 2023-01), p. 205-215
Abstract:
Plain language summary The number of people diagnosed with skin cancer cutaneous melanoma is increasing globally, with Norway having the second highest rate of death due to melanoma in the world. The stage of disease (how much the tumor has spread) determines which treatment is most effective. While early-stage disease is typically considered of low risk, people diagnosed at this stage have a high risk of disease recurrence and a similar chance of survival to those diagnosed at a later disease stage. By researching how long people with melanoma survive based on their disease stage, we gain greater insight into which groups of patients may have an unmet need for therapy. This study aimed to understand how long patients with melanoma in Norway survive after diagnosis, based on their disease stage at diagnosis. The study used patient data from the Cancer Registry of Norway and included only the patients diagnosed with at least stage IIB melanoma from January 2008 to December 2018, unless they had stage IV disease that had not been treated with surgery. This study found that the proportion of patients who survived to 5 years was dependent on the disease stage at diagnosis; however, patients in earlier stages had similar survival to those in later (although not very late) stages of disease. This research shows that patients diagnosed with early-stage melanoma in Norway have an unmet need for treatment options following surgery that address the severity of their risk. This research may help inform decision-making around which treatments patients with early-stage melanoma have access to.
Type of Medium:
Online Resource
ISSN:
1479-6694
,
1744-8301
DOI:
10.2217/fon-2022-0969
Language:
English
Publisher:
Future Medicine Ltd
Publication Date:
2023
Bookmarklink